Cytoprotection & Antioxidant Defence
BPC-157 upregulates endogenous antioxidant systems and protects hepatocyte membrane integrity. Multiple animal models show protection against alcohol-induced, NSAID-induced, and toxic liver injury.
Research Guide
Peptides for Liver Health & Detoxification
The liver performs over 500 essential functions. Research compounds with hepatoprotective, anti-fibrotic, and regenerative properties are an active area of peptide science.
How Peptides May Help
Immune Modulation
Thymosin Alpha-1 enhances T-cell-mediated viral clearance while dampening excessive inflammatory responses. It is approved in 30+ countries for chronic hepatitis B treatment.
Anti-Fibrotic Effects
Hepatic fibrosis is driven by stellate cell activation. Several peptides reduce stellate cell activation and collagen deposition in preclinical models.
Tissue Repair & Regeneration
The liver has remarkable regenerative capacity. Peptides supporting extracellular matrix remodelling and growth factor production may enhance natural recovery.
Antimicrobial Protection
In advanced liver disease, impaired immune function increases susceptibility to bacterial infections. LL-37 provides innate defence against pathogens.
Gut-Liver Axis Support
Intestinal permeability allows bacterial endotoxins to reach the liver via the portal vein. BPC-157's gut mucosal protective effects may indirectly support liver health.
Researched Compounds
BPC-157
RecoveryHepatoprotective gastric pentadecapeptide with extensive preclinical evidence. Multiple animal studies demonstrate protection against alcohol-induced liver damage, NSAID hepatotoxicity, and toxic liver injury.
Mechanism: Cytoprotection, anti-inflammatory signalling, promotion of hepatic regeneration. Also supports the gut-liver axis through mucosal protection.
Thymosin Alpha-1
ImmuneClinically approved immunomodulator for hepatitis treatment in 30+ countries. Enhances T-cell-mediated antiviral responses and promotes viral clearance.
Mechanism: Immune modulation, antiviral support, hepatic immune response regulation.
Most clinically validated peptide for liver-related indications
Research compound
GHK-Cu
Skin & RepairCopper peptide for tissue repair and extracellular matrix remodelling. Stimulates collagen synthesis which may support hepatic repair following injury.
Mechanism: Anti-fibrotic potential through modulation of extracellular matrix turnover and reduction of excessive scar tissue formation.
Tesamorelin
Growth HormoneGrowth hormone-releasing hormone analogue with evidence for visceral fat and hepatic steatosis reduction in HIV-associated lipodystrophy.
Mechanism: Reduces visceral adiposity and hepatic fat content. Specific HIV indication; off-label NAFLD use not supported by Phase 3 data.
Evidence comparison
| Compound | Human Evidence | Honest Verdict |
|---|---|---|
| BPC-157 | None for liver disease | Preclinical gut-barrier/hepatoprotection signal; no human liver-disease trial |
| Thymosin Alpha-1 | Approved in 30+ countries for hepatitis B | Most clinically validated; off-label NAFLD use emerging |
| GHK-Cu | None for liver | Anti-fibrotic preclinical signal; no NAFLD/MASH trial |
| Tesamorelin | HIV-associated lipodystrophy | Specific HIV indication; off-label NAFLD unsupported by Phase 3 |
| Semaglutide/Tirzepatide | Strong (NAFLD/MASH endpoints) | Significant liver-fat reduction in trials (licensed for diabetes/obesity) |
SwissNova Labs products are supplied exclusively for laboratory research purposes. They are not intended to diagnose, treat, cure, or prevent any disease. Information on this page is educational and is not medical advice. Consult a qualified healthcare professional before making health decisions.